Articles tagged with Vaccination
Researchers at Umeå University have made a significant discovery about the diarrhea virus, revealing its ability to survive acidic stomach environments and infect intestines. This understanding could lead to the development of new vaccines, potentially given in edible form, and has implications for tackling diseases like COVID-19.
Recent surveys indicate a fluctuating willingness to be vaccinated, with 60% willing and 51% unwilling; experts propose 12 strategies, including analogy and explanation, to boost vaccine uptake and achieve 100% follow-through.
A new study suggests that shortening the COVID-19 infectious period by half a day could avert up to 1.4 million cases and over 99,000 hospitalizations, saving $209.5 billion in direct medical costs. Expanding treatment to 75% of infected individuals could avert 29.7 million cases and save $856 billion.
Researchers developed an mRNA vaccine that restored tolerance to self-proteins in mice with autoimmune encephalomyelitis, a mouse model for multiple sclerosis. The vaccine suppressed immune responses and promoted regulatory T cells to control the disease.
Researchers at Swansea University have received £230,000 to develop a smart vaccine device that delivers the COVID-19 vaccine and measures its efficacy through monitoring biomarkers in the skin. The device uses microneedles for minimally invasive delivery and offers a personalized vaccination approach.
Researchers suggest that single-dose vaccines may offer greater population benefit due to the speed-versus-efficacy tradeoff. Alternative dose allocation strategies also improve benefits by vaccinating more people sooner while maintaining scheduling for second doses.
A recent study found that nearly 40% of Facebook posts about the HPV vaccine amplified perceived health risks, leading to a false perception of the vaccine's safety. Monique Luisi, an expert in health communication, believes this phenomenon can inform the COVID-19 vaccine rollout and distribution.
Experts discuss microbial-based solutions to combat COVID-19, including vaccine candidates and production platforms. The webinar explores learnings from vaccine development, innovative approaches to address systemic inflammation.
The mRNA-1273 vaccine demonstrated effectiveness in preventing severe COVID-19, with no safety concerns or evidence of enhanced respiratory disease. The trial enrolled over 30,000 participants and showed a significant reduction in symptomatic cases among those who received the vaccine.
The Moderna COVID-19 vaccine has demonstrated a 94.1 percent efficacy in preventing symptomatic COVID-19 infections and severe illness, according to the results of the ongoing phase 3 clinical trial. The study enrolled over 30,000 participants and found that cases of severe COVID-19 occurred only in those who received the placebo.
Researchers at the University of Zurich have developed a genetic engineering method to prevent Toxoplasma gondii parasite production, which causes toxoplasmosis. The new technique uses CRISPR-Cas9 gene editing scissors to switch off essential genes responsible for oocyst formation without leaving unwanted traces.
Researchers found that people infected with COVID-19 retain immunity for at least 8 months through virus-specific memory B cells. This discovery alleviates concerns about vaccine efficacy and provides real hope for long-term protection against the virus.
A recent study found that combining mandatory mask-wearing policies with extensive social distancing can prevent most COVID-19 cases on college campuses, with routine testing also showing high effectiveness. However, the cost of testing may be a barrier for some colleges and universities.
The American College of Physicians (ACP) hosted a virtual COVID-19 Vaccine Forum II to address barriers to optimal vaccine uptake. Panelists emphasized the need for comprehensive public health communications campaigns to refute misinformation and build trust among disproportionately affected minority communities.
A recent study assessed the acceptability of COVID-19 vaccine mandates in the US public, revealing mixed attitudes towards mandates. The study found that while some individuals strongly supported vaccine mandates, others were more hesitant or opposed.
The Advanced Photon Source (APS) has been instrumental in the development of COVID-19 vaccines, allowing for rapid progress through genetic mutations that increase effectiveness. Scientists used APS ultrabright X-ray beams to illuminate virus structures and design vaccine techniques, drugs, and treatments.
A recent national study found that factors such as perceived importance of others, confidence to wear a face covering, and personal importance of use positively associated with intention to wear a face covering. The study suggests that messaging strategies targeting individual intentions and social norms may be more effective than focu...
Researchers achieved rapid development of effective vaccines against COVID-19, highlighting the collaboration between scientists and governments. However, this unprecedented speed revealed alarming fissures between science and policy makers.
A national vaccine strategy is crucial to defeating COVID-19, according to Columbia University's Mailman School of Public Health. The school recommends setting realistic expectations on vaccine effectiveness and promoting universal health coverage for vulnerable populations.
Researchers at Nationwide Children's Hospital found a 10% drop in MMR vaccine uptake among children aged 16 months. The study highlights the need for preventive care visits during the pandemic, despite safety concerns.
Scientists at Scripps Research have developed a vaccine that can deactivate the effects of synthetic cannabinoids in rodents, sequestering drug molecules before they interact with the central nervous system. The approach worked in models simulating smoking and vaping, a common method of use for these drugs.
Research highlights individual-level barriers to COVID-19 vaccination in individuals with severe mental illness, including stigma and lack of access to healthcare. The study identifies system-level solutions, such as improving mental health services and increasing vaccine accessibility, to address these gaps.
Scientists successfully produced C-nucleosides, the basic building blocks of RNA, using an enzyme called YeiN, offering a more efficient and eco-friendly alternative to chemical synthesis. This breakthrough has implications for the production of RNA-based therapeutic products, such as vaccines.
For global success, vaccines must prevent all three: infection, disease progression, and transmission. The authors emphasize prioritizing vulnerable populations and healthcare workers before the wider population.
A survey of 788 US adults found that concerns about side effects were a significant barrier to getting the vaccine. Disparities in willingness to get vaccinated also existed among demographic groups, with younger and white respondents more likely to be willing than older and Black respondents.
Researchers propose five behavioral strategies and a national entity to promote COVID-19 vaccination, including making vaccines free and accessible, leveraging public endorsements, and transforming individual decisions into public acts. The proposed entity should bring together scientists from multiple disciplines to depoliticize pande...
Researchers investigated COVID-19 and Guillain-Barré syndrome, a rare autoimmune condition. The study found no significant association between the two conditions, contradicting previous small case series. The researchers conclude that COVID-19 vaccination is unlikely to cause GBS.
A special report by The BMJ reveals that the UK government has kept its advisors' financial conflicts of interest unpublished, leading to calls for greater transparency. SAGE members have been accused of being unbalanced in their scientific proficiency and favoring certain types of expertise.
The Oxford Covid-19 vaccine has shown a 70.4% overall efficacy rate in phase 3 human trials, with the standard dose regimen showing 62.1% efficacy and the low dose regimen demonstrating 90.0% efficacy. No hospitalizations or severe disease were observed in vaccinated groups.
The pharmaceutical industry made significant strides in 2020, developing tests, therapeutics, and vaccines to combat COVID-19. Companies like Eli Lilly and Regeneron led the way in making antibody therapies, while Moderna used messenger RNA to develop a potential vaccine with promising early trial data.
The FAPESP COVID-19 Research Webinars will address manufacturing and distribution logistics of the COVID-19 vaccine portfolio. The event features expert speakers from leading institutions, including Tiago Rocca, Margareth Dalcolmo, and Prashant Yadav.
A new iGIST method detects pertussis toxin levels, reducing animal testing. The method is more effective and enables detection of lower toxin levels than current methods.
Vaccination uptake in children and adolescents decreased in Colorado following the COVID-19 outbreak. The study used data from the Colorado Immunization Information System to analyze vaccination trends before and after the outbreak.
A nursing researcher reflects on her experience participating in a COVID-19 vaccine trial, discussing the importance of informing patients about possible side effects. The article emphasizes the need for clinicians to prepare their patients for vaccination, ensuring informed consent and minimizing adverse reactions.
Researchers at BIDMC identified the role of antibodies and T cells in protecting against COVID-19, finding that low antibody levels can still provide protection when combined with a strong T cell response. The study's findings have important implications for vaccine development and public health strategies.
The use of immunity passports is a topic of debate, as science is unsure about the duration of immunity and potential risks of reinfection. Experts argue that immunity passports could limit fundamental rights, such as freedom of movement, but also propose respecting the right to move freely for those who cannot spread COVID-19.
Researchers propose guidelines to continue placebo-controlled trials of COVID-19 vaccine candidates even after an effective vaccine is found. This approach aims to address the global pandemic while ensuring valuable data collection from low-risk participants.
A study by St. Petersburg University found that vaccination against tuberculosis with the BCG vaccine can slow down the spread of COVID-19 and reduce its course. The analysis showed a correlation between BCG vaccination and lower mortality rates in countries where national immunization programs are well-established.
A study of 173 countries found that increased testing intensity reduced COVID-19 transmission by 9%. Testing had the greatest influence among interventions, with a tenfold increase in tests to new cases reported reducing transmission. This explains why some countries, like China and Australia, achieved near elimination of COVID-19.
Researchers at Brown University are tracking COVID-19 vaccine adverse events among nursing home residents due to the group's high risk of severe illness. The study uses electronic medical records and aims to identify potential side effects, which may be critical for protecting this vulnerable population.
The 4CMenB vaccine has shown 79% effectiveness in preventing meningococcus group B disease among children and young adults. In a real-world study, nearly all vaccinated cases survived, while unvaccinated cases experienced severe outcomes, including death and long-term injuries.
The COVID-19 Peer Hub program is connecting over 4000 immunisation professionals globally to share ideas and practices to counteract vaccine avoidance. Preliminary findings show that the program has been useful for their work, with 90% of participants reporting positive outcomes.
A DNA-based vaccine candidate has been found to be effective in protecting cynomolgus macaques from the Crimean-Congo hemorrhagic fever virus. The vaccine generated protective antibodies and prevented signs of disease in infected animals, offering a promising potential treatment for human patients.
The study highlights the importance of mucosal immune responses in controlling SARS-CoV-2 infection, particularly in asymptomatic cases. Researchers recommend further research on SIgA antibody responses and developing a nasal vaccine that could be easier to administer and store.
A study of SARS-CoV-2 virus genomes from over 46,000 people with COVID-19 found that most common mutations are neutral for the virus, and do not appear to increase transmissibility. The research team identified 12,706 mutations, including one in the spike protein D614G, which is not associated with increased transmission.
Vaccination of endangered tiger population against canine distemper virus could reduce extinction probability from 15.8% to 5.7%
The Canadian Partnership for Research in Immunotherapy Manufacturing Excellence (CanPRIME) provides hands-on manufacturing training to develop novel biotherapeutics, including vaccines and therapies that incorporate viruses, cells, and genes. Nearly 50 individuals will be trained over five years.
Recent studies published in Annals of Internal Medicine investigate the association between ABO blood groups and SARS-CoV-2 infection risk, as well as vaccine development timelines. Additionally, research highlights the potential benefits of home health care for COVID-19 survivors after hospital discharge.
A new microneedle skin patch has been developed by UConn researchers to provide immunization against infectious diseases through a single administration. The patch triggers a high immune response and offers a long-term protection similar to multiple injections.
A commentary discusses the need to weigh scientific validity against social value in COVID-19 vaccine development, highlighting concerns about long-term efficacy and safety. Vaccination efforts could intensify debates around early deployment, emphasizing the importance of addressing these issues.
Researchers found an inverse correlation between mumps IgG titers and COVID-19 severity in vaccinated individuals. Those with higher mumps antibody levels had lower disease severity, suggesting the MMR vaccine may be protective against COVID-19.
A study published in Health Affairs highlights the crucial role of infrastructure in ensuring COVID-19 vaccine effectiveness, alongside public willingness to be immunized. Greater investment is needed to produce and distribute vaccines efficiently and promote trust in vaccination.
A team of experts recommends five principles to ensure equitable COVID-19 vaccine distribution, including diverse participation in clinical trials and transparent data review. The plan aims to prioritize vulnerable populations and overcome financial barriers to vaccination.
A West Virginia University study suggests that local health departments are crucial in getting the hepatitis B vaccine to those who need it most, particularly individuals at risk of contracting the virus. The study found that partnerships between health departments and local drug treatment programs significantly increased vaccine compl...
The article emphasizes the importance of conducting rigorous evaluation to ensure COVID-19 vaccine safety and efficacy. Historical experience with vaccine development informs regulatory practices, including pre-licensure monitoring for rare adverse events and post-licensure pauses if serious adverse events are detected.
Major measles outbreaks will occur globally in 2021 due to widespread vaccination delays caused by the COVID-19 pandemic. Malnutrition and vitamin A deficiency worsen measles severity, leading to increased deaths and blindness.
A new SARS-CoV-2 mutation, D614G, makes the virus more transmissible but not necessarily more severe, according to a recent study published in Science. The mutated strain replicates faster and is more infectious, but its effectiveness against vaccines remains unknown.
Michigan Technological University and University of Massachusetts researchers develop a way to mimic the body's environment in vaccines, keeping viruses stable through crowding. This method has potential to improve access to vaccinations against various viruses, bypassing the cold chain.
Researchers evaluated all new COVID-19 vaccines approved by FDA over last decade, analyzing premarket development time, clinical evidence, and safety database size. The study found that vaccine approvals took an average of 10 months, with varying levels of evidence and follow-up durations.
A leading ethicist suggests paying people to get the COVID-19 jab to achieve widespread coverage and stamp out infection. The proposal aims to boost vaccination uptake when voluntary schemes prove insufficient, considering financial or 'payment in kind' incentives.